Kidney Function Tests Market - Growth, Trends , COVID-19 Impact , and Forecasts (2022 - 2027)

Market Overview

The Kidney Function Tests Market is expected to register a CAGR of 5.62% during the forecast period, 2022-2027.

Kidney function tests are simple procedures that often use blood or urine to help diagnose problems within the kidneys. COVID-19 has also affected patients' kidney function. According to a study "Association of Proteinuria and Hematuria with Acute Kidney Injury and Mortality in Hospitalized Patients with COVID-19" published in November 2020, more than 40% of admitted patients with COVID-19 showed symptoms of abnormal kidney function, such as albuminuria or hematuria. The market is projected to grow during the violence due to increased screening of patients with corona worldwide. Furthermore, according to a study published in medRXiv in April 2020, in adult patients, COVID-19 urinary incontinence was commonly found in patients with moderate to severe disease. In children, exposure to the urinary tract COVID-19 has been reported among those who suffer from a mild form of COVID-19. Urinary tract infections COVID-19 were detected from day 1 to day 52 after the onset of the disease.

Some of the factors driving the growth of the market include an increase in chronic kidney disease, an increase in awareness about diagnostic methods for kidney function, and technological advances in diagnostic equipment and tools.

According to a study "HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis" published in January 2021, the estimated number of people with diabetes worldwide, and 20 times higher than the number of people living with HIV / AIDS worldwide. Therefore, kidney disease is one of the most common diseases in the world, which is expected to boost market growth as this will increase the need for kidney function tests to control the disease.

In addition, diabetes and high blood pressure are considered major factors in the growing burden of chronic kidney disease worldwide. According to the International Diabetes Atlas tenth Edition 2021, 537 million adults (20-79 years) are living with diabetes, approximately1 in 10. This number is predicted to rise to 643 million by 2030 and 783 million by 2045. Over 3 in 4 adults with diabetes live in low- and middle-income countries.

Additionally, market players embrace a variety of strategies such as product launch, development, collaboration, acquisition, integration, and expansion to maximize market share. For example, in August 2020, RenalytixAI received approval from the Unitd States Food and Drug Administration (FDA) for its new KidneyIntelX test. AI-enabled clinical trials designed to identify and improve clinical management of patients with Type 2 diabetes with rapid progressive kidney disease. The emergence of highly technologically advanced products is expected to further market growth in the forecast period.

However, the high cost of diagnostic procedures and strict regulations are expected to hamper market growth in the near future.

Scope of the Report

As per the scope of the report, kidney function tests are simple procedures that generally use either the blood or urine to help identify issues in the kidneys. The kidney function tests market is segmented by Product Type (Dipsticks, Disposables, and Reagents), Test Type (UrineTests (Urine Protein Tests, Creatinine Clearance Tests, and Microalbumin Tests) and Blood Tests (Serum Creatinine Tests, Glomerular Filtration Rate Tests, and Blood Urea Nitrogen Tests), End User (Hospitals and Clinics, Diagnostic Laboratories, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Dipstick Test Segment is Expected to Hold a Major Market Share in the Kidney Function Tests Market

Dipstick is a type of plastic stick that has a chemical line on it in the form of lines. Dipstick is dipped in urine, and when the color of the ribbon changes, it indicates the presence of abnormal substances such as protein, blood, redness, bacteria, and sugar. This helps to identify a range of kidney and urinary problems such as chronic kidney disease, bladder diseases, and kidney stones.

Report published by National Kidney Foundation Inc. in March 2020 stated that hospitalized people with COVID-19 were at higher risk of serious kidney injury (AKI), which could lead to serious illness and even death. A similar study found that patients with COVID-19, who were hospitalized between March 11 and April 26, 2020, were twice as likely to develop AKI compared to non-COVID patients who developed AKI simultaneously in 2019, which was calculated. 56.9% compared to 25.1%, respectively. In August 2021, ID Genomics (IDG), a Seattle-based company, has invented a dipstick-based, for simultaneous identification for large number of genetic variants of SARS-CoV2 and received a grant of USD 300,000 from National Institute of Health (NIH).

In addition, according to the above source, most patients with serious COVID-19 (AKI) complications are still working on the lower kidneys after recovery. According to the study "Using dipstick urinalysis to predict the development of kidney damage in patients with COVID-19" published in February 2022, the levels of proteinuria and hematuria in dipstick urine analysis can be used to predict AKI and renal replacement therapy (RRT ) in hospitalized patients. by COVID-19.Therefore, an increase in the incidence of kidney failure and chronic kidney failure due to COVID is expected to promote partial growth during the forecast period due to ease of diagnosis and availability.

Globally, rising government efforts to address and treat kidney disease are at the forefront of the dipstick test. In addition, the increase in the number of adults and the growing investment in the field of kidney function testing is driving partial growth. For example, in January 2020, Sweden's Elypta AB collected a USD 7.0 million fund for a urine cancer screening test. Additionally, in February 2019, Healthy.io raised USD 18 million for home urine testing in a Series B sponsorship led by Aleph, with the participation of Samsung Followers and individual investors. Therefore, because of the above factors, the segment may witness growth during the forecast period.

To understand key trends, Download Sample Report